Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CDK9 inhibitors in cancer research.

Literature DB >> 35814933

CDK9 inhibitors in cancer research.

Zhi Huang^1,2, Tianqi Wang¹, Cheng Wang¹, Yan Fan¹.

Abstract

Cyclin dependent kinase 9 (CDK9) plays an essential role in regulating transcriptional elongation. Aberrations in CDK9 activity have been observed in various cancers, which make CDK9 an attractive therapeutic target for cancers. This led to an intensive development of small-molecule CDK9 inhibitors or new emerging strategies, such as proteolysis targeting chimeras (PROTACs). Here, we review the CDK9 modulators in cancer not only for research purposes, but also for therapeutic applications. This journal is © The Royal Society of Chemistry.

Entities: Chemical

Year: 2022 PMID： 35814933 PMCID： PMC9215160 DOI： 10.1039/d2md00040g

Source DB: PubMed Journal: RSC Med Chem ISSN： 2632-8682

Keyword Cloud
References

147 in total

Review 1. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Authors: A M Senderowicz
Journal: Invest New Drugs Date: 1999 Impact factor: 3.850

2. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

Authors: Rong Chen; Michael J Keating; Varsha Gandhi; William Plunkett
Journal: Blood Date: 2005-06-21 Impact factor: 22.113

3. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

Authors: K Lacrima; A Valentini; C Lambertini; M Taborelli; A Rinaldi; E Zucca; C Catapano; F Cavalli; A Gianella-Borradori; D E Maccallum; F Bertoni
Journal: Ann Oncol Date: 2005-04-25 Impact factor: 32.976

4. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.

Authors: A Dey; E T Wong; C F Cheok; V Tergaonkar; D P Lane
Journal: Cell Death Differ Date: 2007-11-02 Impact factor: 15.828

5. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Authors: Paul G Wyatt; Andrew J Woodhead; Valerio Berdini; John A Boulstridge; Maria G Carr; David M Cross; Deborah J Davis; Lindsay A Devine; Theresa R Early; Ruth E Feltell; E Jonathan Lewis; Rachel L McMenamin; Eva F Navarro; Michael A O'Brien; Marc O'Reilly; Matthias Reule; Gordon Saxty; Lisa C A Seavers; Donna-Michelle Smith; Matt S Squires; Gary Trewartha; Margaret T Walker; Alison J-A Woolford
Journal: J Med Chem Date: 2008-07-26 Impact factor: 7.446

6. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.

Authors: Raj N Misra; Hai-yun Xiao; Kyoung S Kim; Songfeng Lu; Wen-Ching Han; Stephanie A Barbosa; John T Hunt; David B Rawlins; Weifang Shan; Syed Z Ahmed; Ligang Qian; Bang-Chi Chen; Rulin Zhao; Mark S Bednarz; Kristen A Kellar; Janet G Mulheron; Roberta Batorsky; Urvashi Roongta; Amrita Kamath; Punit Marathe; Sunanda A Ranadive; John S Sack; John S Tokarski; Nikola P Pavletich; Francis Y F Lee; Kevin R Webster; S David Kimball
Journal: J Med Chem Date: 2004-03-25 Impact factor: 7.446